Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (918)	8/23/2001 10:00:39 PM
From: Skywatcher	Read Replies (2) \| Respond to of 1137

You guys are having a regular Chat Fest in here! I wish I had something to add on a positive note...well, ONXX...howabout that? and CORR down here.. I KNEW I shoulda switched over to ONXX when it got to low 5.s I can't complain, I did get in a bunch, but shoulda just gone with the instincs on that one.... CC

To: Captain Jack who wrote (918)	8/23/2001 10:15:36 PM
From: JEB	Respond to of 1137

As I said, watching the paint dry. Time to break out my book again.

To: Captain Jack who wrote (918)	8/26/2001 11:28:37 AM
From: JEB	Respond to of 1137

Combination Therapy Encouraging for Metastatic Melanoma Source: 411Cancer.com "Cancer Experts leading the way to optimal cancer care." 08/13/2001 The treatment combination consisting of interferon-alpha, thymosin-alpha 1 and dacarbazine provides encouraging anti-cancer responses for metastatic melanoma, according to a recent article in the publication Melanoma Research. Melanoma is a cancer of the skin that usually begins in the form of a mole. The cancer can grow deep into the skin and spread to different parts of the body through blood or lymph vessels. It usually spreads first to lymph nodes that are near the site of cancer origin and when advanced, can spread to organs and other lymph nodes throughout the body. Treatment for advanced or metastatic melanoma may consist of surgery, radiation, chemotherapy and/or biologic therapy. However, the prognosis for patients diagnosed with this disease is poor, as melanoma typically does not respond well to standard therapies. Interferon-alpha and thymosin-alpha 1 are both synthetically produced agents that simulate naturally occurring substances produced by the body which stimulate the immune system. Interferon-alpha has shown to produce anti-cancer effects in the treatment of melanoma. Thymosin-alpha 1, a relatively new agent, has been studied extensively in the treatment of hepatitis and AIDS. Thymosin is produced by the thymus gland and stimulates the initiation of a cascade of immune events including the maturation of T-cells (immune cells involved in the direct attack of foreign cells). Dacarbazine (DTIC) is a standard chemotherapy agent used for the treatment of melanoma. Researchers from Italy recently conducted a small clinical trial evaluating the combination of interferon-alpha, thymosin-alpha 1 and DTIC for the treatment of metastatic melanoma. Following treatment, 50% of patients achieved an anti-cancer response, with 25% achieving a complete disappearance of their cancer. The average duration of survival was nearly 1 year with an average time to disease progression of 5.5 months. No patients discontinued therapy or required a dose reduction due to side effects. All patients were treated on an outpatient basis. These results are encouraging for metastatic melanoma, as response rates and average survival for this disease are typically poor. Patients with metastatic melanoma may wish to speak with their physician about the risks and benefits of participation in a clinical trial further evaluating this combination or other novel treatment regimens. (Melanoma Research, Volume 10, pp 189-192, 2000) (c) CancerConsultants.com Acurian offers a comprehensive listing of melanoma clinical trials that are currently recruiting participants. For more information or to locate a trial, visit our melanoma clinical trials search page. acurian.com